These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 4985515)

  • 1. Studies on the cholera toxin.
    Ungar J; Chariatte N; Stanić M; Varallyay S
    Prog Immunobiol Stand; 1967; 3():357-62. PubMed ID: 4985515
    [No Abstract]   [Full Text] [Related]  

  • 2. Further studies on the cholera toxin and antitoxin.
    Ungar J; Stanić M; Varallyay SJ; Chariatte N
    Prog Immunobiol Stand; 1970; 4():583-9. PubMed ID: 4099025
    [No Abstract]   [Full Text] [Related]  

  • 3. Procholeragenoid: an aggregated intermediate in the formation of choleragenoid.
    Finkelstein RA; Fujita K; LoSpalluto JJ
    J Immunol; 1971 Oct; 107(4):1043-51. PubMed ID: 4999257
    [No Abstract]   [Full Text] [Related]  

  • 4. Vibrio cholerae: production of toxin by a nonpathogenic strain.
    Blachman U; Basu S; Pickett MJ
    J Infect Dis; 1970 Dec; 122(6):540-3. PubMed ID: 4992340
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative studies on the protective value of different antigenic preparations from cholera vibrios.
    Sanyal SC; Narayanaswami A; Mukerjee S
    Indian J Med Res; 1969 Sep; 57(9):1621-8. PubMed ID: 5369787
    [No Abstract]   [Full Text] [Related]  

  • 6. Conversion of cholera exo-enterotoxin (choleragen) to natural toxoid (choleragenoid).
    Finkelstein RA; Peterson JW; Lospalluto JJ
    J Immunol; 1971 Mar; 106(3):868-71. PubMed ID: 4993866
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies on cholera toxin and antitoxin.
    Ungar J; Stanić M; Chariatte N; Varallyay SJ
    J Gen Microbiol; 1970 Nov; 64(1):1-10. PubMed ID: 5516606
    [No Abstract]   [Full Text] [Related]  

  • 8. Antigenic analysis of vibrio culture filtrate and vaccine El Tor vibrio.
    Sanyal SC; Narayanaswami A; Mukerjee S
    J Hyg (Lond); 1969 Sep; 67(3):539-44. PubMed ID: 4980363
    [No Abstract]   [Full Text] [Related]  

  • 9. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholera toxins: purification and preliminary characterization of ileal loop reactive type 2 toxin.
    Coleman WH; Kaur J; Iwert ME; Kasai GJ; Burrows W
    J Bacteriol; 1968 Oct; 96(4):1137-43. PubMed ID: 4971885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of cholera exotoxin in culture filtrates of V. cholerae.
    Holmgren J; Lönnroth I; Ouchterlony O
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1971; 79(3):448. PubMed ID: 4997140
    [No Abstract]   [Full Text] [Related]  

  • 12. Developments with bacterial vaccines: cholera.
    Northrup RS
    Prog Immunobiol Stand; 1971; 5():328-9. PubMed ID: 4349833
    [No Abstract]   [Full Text] [Related]  

  • 13. Intraduodenal inoculation of adult rabbits for evaluating the immunogenicity of genetically attenuated Vibrio cholerae strains.
    García Imia L; Oliva Hernández R; Cedré Marrero B; Valmaseda Pérez T; García Sánchez H; Talavera Coronel A; Pérez Quiñoy JL; Sierra González G
    Lab Anim Sci; 1998 Oct; 48(5):538-41. PubMed ID: 10090073
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunocyte response to a purified bacterial toxin (choleragen) and toxoid: cytokinetics, immunoglobulin class, and specificity.
    Kateley JR; Lyons SF; Friedman H
    J Immunol; 1974 Apr; 112(4):1452-60. PubMed ID: 4592602
    [No Abstract]   [Full Text] [Related]  

  • 15. An effect of cholera toxin on small intestine without direct mucosal contact.
    Serebro HA; McGonagle T; Iber FL; Royall R; Hendrix TR
    Johns Hopkins Med J; 1968 Nov; 123(5):229-32. PubMed ID: 5686426
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholera toxin and toxoid.
    Ungar J; Stanić M; Chariatte N; Varallyay SJ
    Prog Immunobiol Stand; 1971; 5():348-9. PubMed ID: 4660540
    [No Abstract]   [Full Text] [Related]  

  • 17. [Utilization of new findings about cholera toxin for prevention and therapy].
    Holý J
    Cas Lek Cesk; 1982 Apr; 121(15):475. PubMed ID: 7083294
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity to cholera: relation of fraction II of type 2 cholera toxin to vibriocidal antibody.
    Kaur J; Burrows W
    J Bacteriol; 1969 May; 98(2):467-74. PubMed ID: 4977478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antigenic interrelationships of live cholera vaccines and a method of bioassay.
    Dutta NK; Dohadwalla AN; Chakrabarti MC
    J Pathol Bacteriol; 1966 Oct; 92(2):337-43. PubMed ID: 5964374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.